Core Viewpoint - The article discusses the acquisition of 85% stake in REGEN Biotech, Inc. by Aimeike International, a subsidiary of Aimeike, which aims to enhance the company's regenerative medical aesthetics system and expand its international market presence [2][3]. Group 1: Acquisition Details - Aimeike International will pay $190 million in cash for the acquisition, with Aimeike Hong Kong contributing $133 million (70%) and Shou Rui Hong Kong contributing $57 million (30) [3]. - After the transaction, Aimeike will hold a 59.5% stake in REGEN Biotech, Inc., gaining actual control over the company [3]. Group 2: Product and Market Impact - REGEN Biotech, Inc. is known for its leading aesthetic products, including AestheFill and PowerFill, which have received regulatory approvals in multiple countries [4]. - AestheFill, the first imported "youthful needle" approved in China, is expected to enhance Aimeike's existing product offerings and increase the proportion of high-end product revenue [3][4]. Group 3: International Expansion - The acquisition will facilitate resource integration between Aimeike and REGEN Biotech, aiding in the rapid expansion into overseas markets [4]. - REGEN Biotech's products have been recognized for their safety and effectiveness in international markets, having received approvals in 34 countries for AestheFill and 24 countries for PowerFill [4].
【爱美客(300896.SZ)】拟收购AestheFill源头公司,进一步提升国内再生市场话语权——收购事件点评(姜浩)